EVOQUE System

About Edwards Lifesciences

Edwards Lifesciences is a publicly traded, revenue-generating medical device powerhouse with a $46.55B valuation, specializing in structural heart innovations. The company's core business revolves around its pioneering transcatheter aortic valve replacement (TAVR) platform, led by the SAPIEN family of valves, and it is expanding into adjacent high-growth markets like transcatheter mitral and tricuspid therapies. With a deep clinical pipeline and a strong focus on multidisciplinary 'Heart Team' collaboration, Edwards is well-positioned to address the large, underserved global patient population with valvular heart disease. Its recent divestiture of the Critical Care unit to BD allows for intensified focus on its core structural heart franchise.

Therapeutic Areas